ArticleOncotarget2016

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment.

Luuk van Hooren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.